Zymeworks Files Registration Statement For Proposed Initial Public Offering
Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and
commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced
that it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange
Commission (the “SEC”) and a preliminary prospectus with the securities regulatory authorities in each of the provinces and
territories of Canada for a proposed initial public offering of its common shares. The number of common shares to be sold and the
price range for the proposed offering have not yet been determined. Zymeworks has applied to list its common shares on the New York
Stock Exchange and intends to apply to list its common shares on the Toronto Stock Exchange, under the ticker symbol “ZYME” for
both exchanges.
Citigroup Global Markets Inc., Barclays Capital Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers
for the offering. Cannacord Genuity Inc. is acting as a lead manager. Cormark Securities (USA) Limited is acting as a
co-manager.
The Registration Statement relating to the common shares has been filed with the SEC but has not yet become effective. The
common shares may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective.
A preliminary prospectus has been filed with the securities commissions or similar securities regulatory authorities in each of
the provinces and territories of Canada containing important information relating to the common shares. The preliminary prospectus
remains subject to completion or amendment. There will not be any sale or any acceptance of an offer to buy the common shares until
a receipt for the final prospectus has been issued by the relevant securities commissions in Canada.
The offering will be made only by means of a prospectus. The prospectus will contain important detailed information about the
securities offered. Copies of the preliminary prospectus may be obtained, when available, from Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone: (800) 831-9146, or by email at
prospectus@citi.com; Barclays Capital Inc., c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone: (888) 603-5847, or by email at Barclaysprospectus@broadridge.com; or Wells Fargo Securities, LLC,
Attn: Equity Syndicate, 375 Park Avenue, New York, NY 10152, by telephone (800) 326-5897, or by email at cmclientsupport@wellsfargo.com. Copies of the Registration Statement and
preliminary prospectus may also be obtained, when available, from www.sec.gov and www.sedar.com, respectively.
Forward Looking Statements
This press release contains certain forward-looking statements, including statements with regard to Zymeworks’ proposed initial
public offering. Words such as “expects”, “anticipates” and “intends” or similar expressions are intended to identify
forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results
and conditions and no assurance can be given that the initial public offering discussed above will be completed on the terms
described. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which
are beyond Zymeworks’ control, including, without limitation, failure of customary closing conditions and the risk factors and
other matters set forth in Zymeworks’ filings with the SEC and the securities commissions or similar securities regulatory
authorities in each of the provinces and territories of Canada. Zymeworks undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be
required by law.
Investor Inquiries:
David Matousek, 604-678-1388
Senior Manager, Investor Relations & Corporate Communications
ir@zymeworks.com
or
ICR Inc.
Stephanie Carrington, 646-277-1282
stephanie.carrington@icrinc.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170403005653/en/